{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:22:23Z","timestamp":1748406143882,"version":"3.41.0"},"reference-count":57,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"1","license":[{"start":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:00Z","timestamp":1486598400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Background: In spite of allergen-specific immunotherapy (SIT) multiple benefits, its use is restricted in some countries owing to concerns about severe adverse reactions.Objective: To evaluate systemic adverse reactions in patients with atopic dermatitis or allergic asthma, allergic rhinitis and allergic conjunctivitis who received subcutaneous immunotherapy with tyrosine-adsorbed Dermatophagoides and Glycyphagoides dust mites extracts.Methods: Retrospective study of the 2007-2015-period that included 773 patients diagnosed with IgE-mediated diseases, where the safety of allergen-specific immunotherapy was described according to the World Organization of Allergy subcutaneous immunotherapy-induced systemic reactions classification system.Results: 79.7\u00a0% of patients had rhinitis, 54.9\u00a0% asthma, 34.5\u00a0% conjunctivitis and 16.4\u00a0% atopic dermatitis. Out of 12,546 tyrosine-adsorbed extract doses, 45 systemic reactions were recorded: 12 were grade 1 (30\u00a0%), 27 grade 2 (67.5\u00a0%) and 1 was grade 3 (2.5\u00a0%); the reaction rate was 0.35 per 100 administered injections, for an incidence rate of 5.8\u00a0%. No fatal reactions occurred.Conclusion: The frequency of systemic reactions with subcutaneous immunotherapy with Dermatophagoides farinae, Dermatophagoides pteronyssinus and Blomia tropicalis tyrosine-adsorbed extracts was similar to that reported with other extracts.<\/jats:p>","DOI":"10.29262\/ram.v64i1.233","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T21:02:51Z","timestamp":1515531771000},"page":"52-65","source":"Crossref","is-referenced-by-count":3,"title":["Seguridad de la inmunoterapia subcut\u00e1nea con extractos tirosinados de \u00e1caros de polvo dom\u00e9stico en pacientes  con enfermedad al\u00e9rgica","Safety of subcutaneous immunotherapy with tyrosine-adsorbed house dust mite extracts in patients with allergic disease"],"prefix":"10.29262","volume":"64","author":[{"given":"M\u00f3nica Mar\u00eda","family":"Molina-S\u00e1enz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Villa-Arango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"6455","unstructured":"Abbas AK, Lichtman AH, Pillai S. Introduction to immune system. En: Abbas AK, Lichtman AH, Pillai S, editores. Cellular and molecular immunology. S\u00e9ptima edici\u00f3n. Saunders; 2012."},{"key":"6456","unstructured":"Pawankar R, Canonica GW, Holgate ST, Lockey RF. Libro blanco sobre alergia de la WAO. USA: WAO; 2011."},{"key":"6457","unstructured":"ISSAC, The International Study of Asthma and Allergies in Childhood [sitio web]. Disponible en: http:\/\/isaac.auckland.ac.nz\/"},{"key":"6458","doi-asserted-by":"crossref","unstructured":"Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743.","DOI":"10.1016\/S0140-6736(06)69283-0"},{"key":"6459","doi-asserted-by":"crossref","unstructured":"Dennis R, Caraballo L, Garc\u00eda E, Rojas MX, Rond\u00f3n MA, P\u00e9rez A, Aristiabal G. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: A cross-sectional study. BMC Pulm Med. 2012;12:17. DOI: http:\/\/dx.doi.org\/10.1186\/1471-2466-12-17","DOI":"10.1186\/1471-2466-12-17"},{"key":"6460","doi-asserted-by":"crossref","unstructured":"Yepes-N\u00fa\u00f1ez JJ, G\u00f3mez C, Espinoza Y, Cardona R. Impacto de la inmunoterapia subcut\u00e1nea con Dermatophagoides farinae y Dermatophagoides pteronyssinus sobre la calidad de vida de pacientes con rinitis y asma al\u00e9rgica. Biomedica. 2014;34(2):282-290. DOI: http:\/\/dx.doi.org\/10.7705\/biomedica.v34i2.1744","DOI":"10.7705\/biomedica.v34i2.1744"},{"key":"6461","doi-asserted-by":"crossref","unstructured":"Calder\u00f3n MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011;127(1):30-38. DOI: http:\/\/dx.doi.org\/10.1016\/j.jaci.2010.08.024","DOI":"10.1016\/j.jaci.2010.08.024"},{"key":"6462","unstructured":"Zubeldia JM, Baeza ML, J\u00e1uregui I, Senent C. Libro de las enfermedades al\u00e9rgicas. Espa\u00f1a; Fundaci\u00f3n BBVA\/SEAIC Fundaci\u00f3n; 2012."},{"key":"6463","unstructured":"Bousquet J, Lockey R, Mailing HJ, editores. Inmunoterapia con alergenos. Vacunas terap\u00e9uticas para las enfermedades al\u00e9rgicas. Documento de opini\u00f3n de la OMS. WHO: Madrid, Espa\u00f1a; 2000."},{"key":"6464","doi-asserted-by":"crossref","unstructured":"Demoly P, Calder\u00f3n MA. Dosing and efficacy in specific immunotherapy. Allergy. 2011;66 Suppl 95:38-40. DOI: http:\/\/dx.doi.org\/10.1111\/j.1398-9995.2011.02631.x","DOI":"10.1111\/j.1398-9995.2011.02631.x"},{"key":"6465","unstructured":"S\u00e1nchez J, Restrepo M, D\u00edez S, Cardona R. Comparaci\u00f3n del efecto cl\u00ednico de la inmunoterapia en pacientes con asma al\u00e9rgica seg\u00fan la edad y el patr\u00f3n de sensibilizaci\u00f3n. Alerg Asma Inmunol Pediatr. 2014;23(1):6-14. Disponible en: http:\/\/www.medigraphic.com\/pdfs\/alergia\/al-2014\/al141b.pdf"},{"key":"6466","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Cuesta E, Aragoneses-Gilsanz E, Mart\u00edn-Garc\u00eda C, Berges-Gimeno P, Gonz\u00e1lez-Mancebo E, Cuesta-Herranz J. Immunotherapy with depigmented glutaraldehyde-polymerized extracts: Changes in quality of life. Clin Exp Allergy. 2005;35(5):572-578. DOI: 10.1111\/j.1365-2222.2005.02245.","DOI":"10.1111\/j.1365-2222.2005.02245.x"},{"key":"6467","doi-asserted-by":"crossref","unstructured":"Novak N, Bieber T, Hoffmann M, Folster-Holst R, Homey B, Werfel T, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol. 2012;130(4):925-931. DOI: http:\/\/dx.doi.org\/10.1016\/j.jaci.2012.08.004","DOI":"10.1016\/j.jaci.2012.08.004"},{"key":"6468","doi-asserted-by":"crossref","unstructured":"Senna G, Calderon M, Makatsori M, Ridolo E, Passalacqua G. An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2011;11(4):375-380. DOI: http:\/\/dx.doi.org\/10.1097\/ACI.0b013e328348a7cd","DOI":"10.1097\/ACI.0b013e328348a7cd"},{"key":"6469","doi-asserted-by":"crossref","unstructured":"Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006;61(2):151-165. DOI: 10.1111\/j.1398-9995.2006.01002.x","DOI":"10.1111\/j.1398-9995.2006.01002.x"},{"key":"6470","doi-asserted-by":"crossref","unstructured":"Akdis CA, Barlan IB, Bahceciler N, Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy. 2006;61 Suppl 81:11-14. DOI: 10.1111\/j.1398-9995.2006.01159.x","DOI":"10.1111\/j.1398-9995.2006.01159.x"},{"key":"6471","doi-asserted-by":"crossref","unstructured":"Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology\/European Academy of Allergy and Clinical Immunology\/PRACTAL consensus report. J Allergy Clin Immunol. 2013;131(5):1288-1296.e3. DOI: http:\/\/dx.doi.org\/10.1016\/j.jaci.2013.01.049","DOI":"10.1016\/j.jaci.2013.01.049"},{"key":"6472","doi-asserted-by":"crossref","unstructured":"Nelson HS. Immunotherapy for inhalant allergens. En: Adkison F Jr JR, \u200eBochner BS, Burks AW, editores. Middleton\u2019s allergy: Principles and practice. S\u00e9ptima edici\u00f3n. Canad\u00e1: Elsevier; 1657-1677.","DOI":"10.1016\/B978-0-323-05659-5.00095-4"},{"key":"6473","unstructured":"L\u00f3pez-Piedrahita E, S\u00e1nchez-Caraballo JM, Ram\u00edrez-Girado RH, Cardona-Villa R. Efectividad de la inmunoterapia con alergenos en pacientes con queratoconjuntivitis vernal. Rev Alerg Mex. 2013;60(1):11-16."},{"key":"6474","doi-asserted-by":"crossref","unstructured":"Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specifi c immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116(3):608-613. DOI: http:\/\/dx.doi.org\/10.1016\/j.jaci.2005.06.004","DOI":"10.1016\/j.jaci.2005.06.004"},{"key":"6475","doi-asserted-by":"crossref","unstructured":"Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL- 10 responses and blocking IgG activity. J Immunol. 2004;172(5):3252-3259. DOI: https:\/\/doi.org\/10.4049\/jimmunol.172.5.3252","DOI":"10.4049\/jimmunol.172.5.3252"},{"key":"6476","doi-asserted-by":"crossref","unstructured":"D\u00edez-Zuluaga LS, Cardona-Villa R, Restrepo-Colorado MN, S\u00e1nchez-Caraballo JM. Inmunoterapia con al\u00e9rgenos, \u00bfcu\u00e1ndo y por qu\u00e9? IATREIA. 2015;28(1):55-65. Disponible en: http:\/\/www.redalyc.org\/articulo.oa?id=180533008007","DOI":"10.17533\/udea.iatreia.17755"},{"key":"6477","doi-asserted-by":"crossref","unstructured":"Gozde Kanmaz H, Harmanci K, Razi C, Kose G, Cengizlier MR. Specific immunotherapy improves asthma related quality of life in childhood. Allergol Immunopathol. 2011;39(2):68-72. DOI: http:\/\/dx.doi.org\/10.1016\/j.aller.2010.04.005","DOI":"10.1016\/j.aller.2010.04.005"},{"key":"6478","doi-asserted-by":"crossref","unstructured":"Alvaro M, Sancha J, Larramona H, Lucas JM, Mesa M, Tabar AI, et al. Allergen-specific immunotherapy: Update on immunological mechanisms. Allergol Immunopathol (Madr). 2013;41(4):265-272. DOI: http:\/\/dx.doi.org\/10.1016\/j.aller.2012.07.018","DOI":"10.1016\/j.aller.2012.07.018"},{"key":"6479","unstructured":"Guardia-Mart\u00ednez P, Moreno-Aguilar C, Tabar-Purroy AI, editores. Inmunoterapia con al\u00e9rgenos en el tratamiento de las enfermedades al\u00e9rgicas. Espa\u00f1a: Comit\u00e9 de Inmunoterapia, Sociedad Espa\u00f1ola de Alergolog\u00eda e Inmunolog\u00eda Cl\u00ednica; 2010. Disponible en: http:\/\/www.seaic.org\/wp-content\/plugins\/download-monitor\/download.php?id=Inmunoterapia-con-Alergenos-SEAIC2010.pdf"},{"key":"6480","doi-asserted-by":"crossref","unstructured":"Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(2):319-325. DOI: http:\/\/dx.doi.org\/10.1016\/j.jaci.2005.11.014","DOI":"10.1016\/j.jaci.2005.11.014"},{"key":"6481","doi-asserted-by":"crossref","unstructured":"Corrigan CJ, Kettner J, Doemer , Cromwell O, Narkus A; Study Group. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005;60(6):801-807. DOI: http:\/\/dx.doi.org\/10.1111\/j.1398-9995.2005.00790.x","DOI":"10.1111\/j.1398-9995.2005.00790.x"},{"key":"6482","doi-asserted-by":"crossref","unstructured":"Wheeler AW, Moran DM, Robins BE, Driscoll A. L-tyrosine as an immunological adjuvant. Int Arch Allergy Appl Immunol. 1982;69(2):113-119.","DOI":"10.1159\/000233157"},{"key":"6483","unstructured":"Ferrer M, Burches E, Pel\u00e1ez A, Mu\u00f1oz A, Hern\u00e1ndez D, Basomba A, et al. Double-blind placebo controlled study of immunotherapy with Parietaria judaica: Clinical efficacy and tolerance. J Investig Allergol Clin Immunol. 2005;15(4):283-292."},{"key":"6484","doi-asserted-by":"crossref","unstructured":"Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125(3):569-574, 574.e1-574.e7. DOI: http:\/\/dx.doi.org\/10.1016\/j.jaci.2009.10.060","DOI":"10.1016\/j.jaci.2009.10.060"},{"key":"6485","doi-asserted-by":"crossref","unstructured":"Rank MA, Bernstein DI. Improving the safety of immunotherapy. J Allergy Clin Immunol Pract. 2014;2(2):131-5. DOI: http:\/\/dx.doi.org\/10.1016\/j.jaip.2013.09.01","DOI":"10.1016\/j.jaip.2013.09.017"},{"key":"6486","unstructured":"Ojeda-Fern\u00e1ndez P. Manejo pr\u00e1ctico de la inmunoterapia (I). En: Pel\u00e1ez-Hern\u00e1ndez, editor. Tratado de alergolog\u00eda cl\u00ednica. Espa\u00f1a: Erg\u00f3n; 2007. p. 364-378."},{"key":"6487","doi-asserted-by":"crossref","unstructured":"Ameal A, Vega-Chicote JM, Fern\u00e1ndez S, Miranda A, Carmona MJ, Rond\u00f3n MC, et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy. 2005;60(9):1178-1183.","DOI":"10.1111\/j.1398-9995.2005.00862.x"},{"key":"6488","doi-asserted-by":"crossref","unstructured":"Branco Ferreira M, Sp\u00ednola Santos A, Pereira Santos MC, Palma Carlos ML, Pereira Barbosa MA, Palma Carlos AG. Efficacy and safety of specific immunotherapy with a modified mite extract. Allergol Immunopathol (Madr). 2005;33(2):80-85. DOI: http:\/\/dx.doi.org\/10.1157\/13072918","DOI":"10.1157\/13072918"},{"key":"6489","doi-asserted-by":"crossref","unstructured":"Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E; Immunotherapy Committee, Sociedad Espa\u00f1ola de Alergolog\u00eda e Inmunolog\u00eda Cl\u00ednica. Immunotherapy safety: A prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy. 2004;34(4):527-531.","DOI":"10.1111\/j.1365-2222.2004.1819.x"},{"key":"6490","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez N, Ibero M, Ridao M, Artigas R, Vi\u00f1as M, Castillo MJ. Safety of specific immunotherapy using a depigmented and polymerized extract of Dermatophagoides pteronyssinus in children under five years of age. Allergol Immunopathol (Madr). 2011;39(5):267-270. DOI: http:\/\/dx.doi.org\/10.1016\/j.aller.2010.09.002","DOI":"10.1016\/j.aller.2010.09.002"},{"key":"6491","doi-asserted-by":"crossref","unstructured":"Casanovas M, Mart\u00edn R, Jim\u00e9nez C, Caballero R, Fern\u00e1ndez-Caldas E. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol. 2006;139(2):153-158.","DOI":"10.1159\/000090392"},{"key":"6492","unstructured":"Sager A, Renner BG. Safety aspects and course of allergen specific immunotherapy with a depigmented, polymerized allergen extract. Allergol J. 2004;13:386-391."},{"key":"6493","doi-asserted-by":"crossref","unstructured":"Wong PH, Adams KE, Carlson GS, Quinn JM. Experience with epinephrine delivery in immunotherapy associated systemic reactions. Ann Allergy Asthma Immunol. 2016;116(2):166-168. DOI: http:\/\/dx.doi.org\/10.1016\/j.anai.2015.11.009","DOI":"10.1016\/j.anai.2015.11.009"},{"key":"6494","doi-asserted-by":"crossref","unstructured":"Gamboa P, Gonz\u00e1lez G, Jauregui I, Jorr\u00f3 G, Molero I, Eseverri JL, et al. A prospective and multicenter safety-monitoring study of a short up-dosing schedule of immunotherapy with amass-units-standardized extract of mites. Allergol Immunopathol (Madr). 2004;32(1):13-17. Disponible en: http:\/\/www.elsevier.es\/en-revista-allergologia-et-immunopathologia-105-articulo-a-prospective-multicenter-safety-monitoring-study-13057764","DOI":"10.1157\/13057764"},{"key":"6495","doi-asserted-by":"crossref","unstructured":"Cardona R, Lopez E, Beltr\u00e1n J, S\u00e1nchez J. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study. Allergol Immunopathol (Madr). 2014;42(2)90-95. DOI: http:\/\/dx.doi.org\/10.1016\/j.aller.2012.07.005","DOI":"10.1016\/j.aller.2012.07.005"},{"key":"6496","doi-asserted-by":"crossref","unstructured":"Cardona Villa R, Chinchilla Mej\u00eda CF, Ram\u00edrez Giraldo RH, Olivares Gomez MM, Calvo V, Maspero JF. Poster 2010: A study assessing the safety and efficacy of subcutaneous immunotherapy with a dust mite vaccine with the adjuvant l-tyrosine in a highly sensitized population in a Latin American city. World Allergy Organ J. 2014; 7(Suppl 1):P22. DOI: http:\/\/dx.doi.org\/10.1186\/1939-4551-7-S1-P22","DOI":"10.1186\/1939-4551-7-S1-P22"},{"key":"6497","doi-asserted-by":"crossref","unstructured":"[No authors listed]. CSM update. Desensitising vaccines. Br Med J. 1986;293\/5552):948. Disponible en: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1341725\/pdf\/bmjcred00256-0048.pdf","DOI":"10.1136\/bmj.293.6552.948"},{"key":"6498","doi-asserted-by":"crossref","unstructured":"Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1.S55. DOI: http:\/\/dx.doi.org\/10.1016\/j.jaci.2010.09.034","DOI":"10.1016\/j.jaci.2010.09.034"},{"key":"6499","doi-asserted-by":"crossref","unstructured":"Greenberg MA, Kaufman CR, Gonzalez GE, Rosenblatt CD, Smith LJ, Summers RJ. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol. 1986;77(6):865-870. DOI: http:\/\/dx.doi.org\/10.1016\/0091-6749(86)90385-4","DOI":"10.1016\/0091-6749(86)90385-4"},{"key":"6500","doi-asserted-by":"crossref","unstructured":"Matloff SM, Bailit IW, Parks P, Madden N, Greineder DK. Systemic reactions to immunotherapy. Allergy Proc. 1993;14(5):347-350. DOI: https:\/\/doi.org\/10.2500\/108854193778774001","DOI":"10.2500\/108854193778774001"},{"key":"6501","doi-asserted-by":"crossref","unstructured":"Hepner MJ, Ownby DR, Anderson JA, Rowe MS, Sears-Ewald D, Brown EB. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol. 1990;86(3 Pt 1):407-11.","DOI":"10.1016\/S0091-6749(05)80105-8"},{"key":"6502","doi-asserted-by":"crossref","unstructured":"Bousquet J, Lockey R, Malling HJ. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998;44 Suppl 1:2-42.","DOI":"10.1111\/j.1398-9995.1998.tb04930.x"},{"key":"6503","doi-asserted-by":"crossref","unstructured":"Tabar A, Garc\u00eda B, Rodr\u00edguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety monitoring study of immunotherapy with biologically standardized extracts. Allergy. 1993;48(6):450-453. DOI: DOI: http:\/\/dx.doi.org\/10.1111\/j.1398-9995.1993.tb00743.x","DOI":"10.1111\/j.1398-9995.1993.tb00743.x"},{"key":"6504","doi-asserted-by":"crossref","unstructured":"Hejjaoui A, Ferrando D, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992;89(5):925-933. DOI: http:\/\/dx.doi.org\/10.1016\/0091-6749(92)90214-M","DOI":"10.1016\/0091-6749(92)90214-M"},{"key":"6505","doi-asserted-by":"crossref","unstructured":"Theododopoulos DS, Lockey RF. Allergen immunotherapy: guidelines, update and recommendations of the World Health Organization. Allergy Asthma Proc. 2000;218(3):159-166.","DOI":"10.2500\/108854100778149007"},{"key":"6506","doi-asserted-by":"crossref","unstructured":"Lockey R, Nicoara-Kasti G, Theodoropoulos D, Bukantz S. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol. 2001;87(1 Suppl. 1):47-55.","DOI":"10.1016\/S1081-1206(10)62195-3"},{"key":"6507","doi-asserted-by":"crossref","unstructured":"Malling HJ, Weeke B. Position paper: Immunotherapy. Allergy. 1993;48 Suppl 14:9-35. DOI: DOI: http:\/\/dx.doi.org\/10.1111\/j.1398-9995.1993.tb04754.x","DOI":"10.1111\/j.1398-9995.1993.tb04754.x"},{"key":"6508","doi-asserted-by":"crossref","unstructured":"Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79(4):660-677.","DOI":"10.1016\/S0091-6749(87)80164-1"},{"key":"6509","doi-asserted-by":"crossref","unstructured":"Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol. 1993;92(1 Pt 1):6-15.","DOI":"10.1016\/0091-6749(93)90030-J"},{"key":"6510","doi-asserted-by":"crossref","unstructured":"Hepner MJ, Ownby DR, Anderson JA, Rowe MS, Sears-Ewald D, Brown EB. Risk of systemic reactions in patients taking betablocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol. 1990;86(3 Pt 1):407-411.","DOI":"10.1016\/S0091-6749(05)80105-8"},{"key":"6511","doi-asserted-by":"crossref","unstructured":"Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf. 2000;238(4):323-332.","DOI":"10.2165\/00002018-200023040-00005"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/233\/2601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/viewFile\/233\/439","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/233\/440","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/233\/602","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/233\/439","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/233\/2601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T01:35:12Z","timestamp":1748396112000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,9]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v64i1.233","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}